يعرض 1 - 10 نتائج من 17 نتيجة بحث عن '"Yan Y. Degenhardt"', وقت الاستعلام: 0.92s تنقيح النتائج
  1. 1
    Supplementary Data from Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

    المؤلفون: Sarah P. Blagden, Johann S. de Bono, Richard Wilson, Mohammed M. Dar, Thomas A. Lampkin, Sharon C. Murray, Deborah A. Smith, Alicia J. Allred, Yan Y. Degenhardt, Hanine Medani, Jorge Barriuso, Anne B. Taegtmeyer, Timothy A. Yap, Andre T. Brunetto, Rohini Sharma, Douglas Barker, David Olmos

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa656e44c9db5425b374f6954cb9ce23
    https://doi.org/10.1158/1078-0432.22441227

    أضف إلى المفضلة
  2. 2
    Data from Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

    المؤلفون: Sarah P. Blagden, Johann S. de Bono, Richard Wilson, Mohammed M. Dar, Thomas A. Lampkin, Sharon C. Murray, Deborah A. Smith, Alicia J. Allred, Yan Y. Degenhardt, Hanine Medani, Jorge Barriuso, Anne B. Taegtmeyer, Timothy A. Yap, Andre T. Brunetto, Rohini Sharma, Douglas Barker, David Olmos

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff23bf4b14372b8aa854f554ab505b1
    https://doi.org/10.1158/1078-0432.c.6518349

    أضف إلى المفضلة
  3. 3
    Supplementary Figure 1 from Molecular Target Class Is Predictive of In vitro Response Profile

    المؤلفون: Richard Wooster, Mary Ann Hardwicke, Kurt Auger, Ronald Wegrzyn, Christopher Moy, Elizabeth McNeil, Stephen Eastman, Yuan H. Wen, Junping Jing, Yan Y. Degenhardt, Kurtis E. Bachman, Joel Greshock

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f1e6751057df620513ddd9c17b2f7df
    https://doi.org/10.1158/0008-5472.22386564.v1

    أضف إلى المفضلة
  4. 4
    Supplementary Methods, Figure Legend from Molecular Target Class Is Predictive of In vitro Response Profile

    المؤلفون: Richard Wooster, Mary Ann Hardwicke, Kurt Auger, Ronald Wegrzyn, Christopher Moy, Elizabeth McNeil, Stephen Eastman, Yuan H. Wen, Junping Jing, Yan Y. Degenhardt, Kurtis E. Bachman, Joel Greshock

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c195ebe7d6e489556ace687a872484
    https://doi.org/10.1158/0008-5472.22386561

    أضف إلى المفضلة
  5. 5
    Supplementary Table 1 from Molecular Target Class Is Predictive of In vitro Response Profile

    المؤلفون: Richard Wooster, Mary Ann Hardwicke, Kurt Auger, Ronald Wegrzyn, Christopher Moy, Elizabeth McNeil, Stephen Eastman, Yuan H. Wen, Junping Jing, Yan Y. Degenhardt, Kurtis E. Bachman, Joel Greshock

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee5090785b43eb994e89bf47e909aaf
    https://doi.org/10.1158/0008-5472.22386558.v1

    أضف إلى المفضلة
  6. 6
    Supplementary Table 3 from Molecular Target Class Is Predictive of In vitro Response Profile

    المؤلفون: Richard Wooster, Mary Ann Hardwicke, Kurt Auger, Ronald Wegrzyn, Christopher Moy, Elizabeth McNeil, Stephen Eastman, Yuan H. Wen, Junping Jing, Yan Y. Degenhardt, Kurtis E. Bachman, Joel Greshock

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56442c57cdf5545781edb9f6c5e2c710
    https://doi.org/10.1158/0008-5472.22386552

    أضف إلى المفضلة
  7. 7
    Supplementary Table 2 from Molecular Target Class Is Predictive of In vitro Response Profile

    المؤلفون: Richard Wooster, Mary Ann Hardwicke, Kurt Auger, Ronald Wegrzyn, Christopher Moy, Elizabeth McNeil, Stephen Eastman, Yuan H. Wen, Junping Jing, Yan Y. Degenhardt, Kurtis E. Bachman, Joel Greshock

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9206933abe5e75de3cf5dd6918ebea65
    https://doi.org/10.1158/0008-5472.22386555.v1

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.

    المؤلفون: Mohammad HP; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Smitheman KN; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Kamat CD; Oncology Department, Johns Hopkins University, Baltimore, MD 21231, USA., Soong D; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Federowicz KE; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Van Aller GS; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Schneck JL; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., Carson JD; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., Liu Y; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Butticello M; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Bonnette WG; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., Gorman SA; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Degenhardt Y; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Bai Y; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., McCabe MT; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Pappalardi MB; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Kasparec J; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Tian X; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., McNulty KC; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Rouse M; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., McDevitt P; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., Ho T; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., Crouthamel M; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Hart TK; Safety Assessment Department, GlaxoSmithKline, Upper Merion, PA 19406, USA., Concha NO; Platform Technology and Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA., McHugh CF; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Miller WH; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Dhanak D; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Tummino PJ; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Carpenter CL; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Johnson NW; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA., Hann CL; Oncology Department, Johns Hopkins University, Baltimore, MD 21231, USA., Kruger RG; Cancer Epigenetics Department, GlaxoSmithKline, Collegeville, PA 19426, USA. Electronic address: ryan.g.kruger@gsk.com.

    المصدر: Cancer cell [Cancer Cell] 2015 Jul 13; Vol. 28 (1), pp. 57-69.

    نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

    بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

    مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Benzoates/*administration & dosage , Cyclopropanes/*administration & dosage , DNA Methylation/*drug effects , Enzyme Inhibitors/*administration & dosage , Histone Demethylases/*antagonists & inhibitors , Lung Neoplasms/*drug therapy , Small Cell Lung Carcinoma/*drug therapy, Administration, Oral ; Animals ; Antineoplastic Agents/pharmacology ; Benzoates/pharmacology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cyclopropanes/pharmacology ; Enzyme Inhibitors/pharmacology ; Epigenesis, Genetic/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Histone Demethylases/genetics ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mice ; Molecular Sequence Data ; Small Cell Lung Carcinoma/genetics ; Small Cell Lung Carcinoma/pathology ; Xenograft Model Antitumor Assays

    View record from ScienceDirect Full Text Finder
    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

    المؤلفون: Wyce A; Cancer Epigenetics DPU, Oncology R and D GlaxoSmithKline, Collegeville, PA, USA., Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O

    المصدر: Oncotarget [Oncotarget] 2013 Dec; Vol. 4 (12), pp. 2419-29.

    نوع المنشور: Journal Article

    بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE

    مواضيع طبية MeSH: Benzodiazepines/*pharmacology , Nuclear Proteins/*antagonists & inhibitors , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Protein Serine-Threonine Kinases/*antagonists & inhibitors, Animals ; Apoptosis/drug effects ; Cell Growth Processes/physiology ; Cell Line, Tumor ; Down-Regulation ; Gene Expression Profiling ; Humans ; Male ; Mice ; Mice, SCID ; Prostatic Neoplasms, Castration-Resistant/enzymology ; Prostatic Neoplasms, Castration-Resistant/pathology ; Xenograft Model Antitumor Assays

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

    المؤلفون: Jing J; Cancer Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA., Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y

    المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2012 Mar; Vol. 11 (3), pp. 720-9. Date of Electronic Publication: 2011 Dec 14.

    نوع المنشور: Journal Article

    بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

    مواضيع طبية MeSH: Biomarkers, Tumor/*genetics , MAP Kinase Kinase 1/*antagonists & inhibitors , MAP Kinase Kinase 2/*antagonists & inhibitors , Pyridones/*pharmacology , Pyrimidinones/*pharmacology, Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/metabolism ; Blotting, Western ; Cell Line, Tumor ; Cell Survival/drug effects ; Cell Survival/genetics ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Dual Specificity Phosphatase 6/genetics ; Dual Specificity Phosphatase 6/metabolism ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/drug effects ; HeLa Cells ; Humans ; MAP Kinase Kinase 1/genetics ; MAP Kinase Kinase 1/metabolism ; MAP Kinase Kinase 2/genetics ; MAP Kinase Kinase 2/metabolism ; Molecular Structure ; Mutation ; Oligonucleotide Array Sequence Analysis ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Prognosis ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Pyridones/chemistry ; Pyrimidinones/chemistry ; Transcriptome ; raf Kinases/genetics ; raf Kinases/metabolism ; ras Proteins/genetics ; ras Proteins/metabolism

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء